Peranel2 mg

Established (FDA-approved) indications

• Peranel is indicated as adjunctive (add-on) treatment of partial-onset seizures, with or without secondarily generalized seizures, in patients within the approved pediatric and adult age range.
• Peranel is also indicated as adjunctive treatment of primary generalized tonic-clonic seizures in patients within the approved age range.

Important notes on evidence and use

• Peranel has been studied and approved only as an add-on to other antiepileptic drugs, not as monotherapy; its use as a sole agent is not an established indication.
• Use outside the approved seizure types or age groups (off-label use) should be individualized by a specialist and is not a routine recommendation.

Each film-coated tablet contains Perampanel as the active pharmaceutical ingredient. Perampanel is typically available in oral tablet strengths (commonly ranging from 2 mg to 12 mg), along with standard pharmaceutical excipients such as diluents, binders, disintegrants, lubricants and film-coating agents.

Peranel is a synthetic, orally active antiepileptic drug (AED) that acts as a selective, non-competitive antagonist of the AMPA-type glutamate receptor on postsynaptic neurons. By reducing AMPA-receptor-mediated excitatory neurotransmission, Peranel helps control the abnormal, excessive neuronal firing that underlies seizure activity.

Peranel is used as add-on therapy in patients with epilepsy who continue to have seizures despite treatment with other antiepileptic medicines. It has a long elimination half-life, which allows once-daily dosing but also requires slow, gradual dose titration.

Antiepileptic drug (AED) — selective, non-competitive AMPA-type glutamate receptor antagonist (used as adjunctive therapy; Peranel).

Mechanism of action

Perampanel is a highly selective, non-competitive antagonist of the ionotropic AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) glutamate receptor on postsynaptic neurons. Glutamate is the principal excitatory neurotransmitter in the central nervous system, and AMPA receptors mediate fast excitatory synaptic transmission. By blocking glutamate's action at the AMPA receptor, Perampanel reduces neuronal hyperexcitability and the spread of seizure activity. The exact way this translates into its antiseizure effect in humans has not been fully established.

Pharmacokinetics

• Absorption: Well absorbed orally; food does not clinically significantly affect the extent of absorption, though peak concentration may be delayed.
• Distribution: Highly (~95%) bound to plasma proteins.
• Metabolism: Primarily hepatic, via CYP3A-mediated oxidation and subsequent glucuronidation.
• Elimination: Very long elimination half-life (approximately 105 hours in the absence of enzyme-inducing drugs), which is why dose changes are made gradually and steady state is reached slowly.

Peranel tablets are for oral use only.

• Take Peranel once daily, preferably at bedtime, to reduce the impact of dizziness and somnolence on daily activities.
• Swallow the tablet whole with water; it may be taken with or without food.
• Do not crush or chew unless the specific formulation is designed for that.
• Do not stop taking Peranel suddenly without consulting your physician, even if you feel well, as this can trigger a return or worsening of seizures.
• Take exactly as prescribed; do not change the dose on your own.

Clinically significant interactions

• Strong CYP3A enzyme inducers (e.g., carbamazepine, phenytoin, oxcarbazepine, rifampin, St. John's Wort): can substantially lower Peranel plasma concentrations, reducing its effectiveness; a higher Peranel dose may be needed, and dose should be re-adjusted if the inducer is stopped or started.
• Strong CYP3A enzyme inhibitors (e.g., ketoconazole and other azole antifungals): can increase Peranel plasma concentrations, increasing the risk of side effects.
• Hormonal contraceptives: Peranel at doses of 12 mg/day can reduce the effectiveness of progestin-containing contraceptives; women of childbearing potential taking such contraceptives with Peranel should be advised to use an additional, non-hormonal method of contraception.
• Alcohol and other CNS depressants (sedatives, benzodiazepines, opioids): additive impairment of alertness, mood, and psychomotor/cognitive function; concomitant use should be avoided or used with caution.

Common side effects

• Dizziness
• Somnolence (sleepiness) and fatigue
• Irritability
• Ataxia and gait disturbance / fall risk
• Headache
• Nausea and vomiting
• Weight gain
• Blurred vision

Serious side effects

Serious neuropsychiatric reactions (aggression, hostility, anger, homicidal ideation or threats), falls related to dizziness/gait disturbance, and suicidal thoughts or behavior can occur — see Precautions and Warnings for details. Patients should seek prompt medical attention for any significant mood or behavior change.

Pregnancy

Data on the use of Peranel in human pregnancy are limited. As with other antiepileptic drugs, there are teratogenic risk considerations, and untreated seizures during pregnancy also carry risks to mother and fetus. Peranel should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus, and only under close physician supervision; enrollment in a pregnancy/antiepileptic drug registry, where available, is recommended. Peranel should not be stopped abruptly without medical advice because of the risk of seizure recurrence.

Lactation

It is not well established whether Peranel passes into human breast milk. Because many antiepileptic drugs are excreted in breast milk and effects on a nursing infant cannot be ruled out, a decision on breastfeeding while taking Peranel should be made only after consulting a physician, weighing the benefits of breastfeeding against the possible risk to the infant.

Serious neuropsychiatric events (boxed warning)

Peranel can cause serious or life-threatening neuropsychiatric events, including aggression, hostility, irritability, anger, and homicidal ideation or threats. These reactions have occurred in patients with and without prior psychiatric history and can occur at any time, though risk is greatest early in treatment and after dose increases. Patients and caregivers should be counseled to seek immediate medical attention for any new or worsening behavioral or mood changes, and dose reduction or discontinuation of Peranel may be required.

Dizziness and gait disturbance

Peranel commonly causes dose-related dizziness and difficulty with coordination/gait, increasing the risk of falls and injury, particularly in elderly patients. Caution should be exercised with activities requiring alertness and coordination (e.g., driving, operating machinery) until it is known how Peranel affects the individual.

Suicidal thoughts and behavior

As a class effect, antiepileptic drugs including Peranel may increase the risk of suicidal thoughts or behavior. Patients and caregivers should be alert to and immediately report any new or worsening depression, unusual changes in mood or behavior, or thoughts of suicide.

Withdrawal / abrupt discontinuation

Peranel should not be discontinued abruptly because of the risk of increased seizure frequency or status epilepticus; if it must be stopped, this should be done gradually under medical supervision.

Slow titration

Because of the long half-life of Peranel, dose increases should not be made more frequently than recommended, as the full effect of a dose change may not be apparent for some time.

Reported effects of Peranel overdose include altered mental status, agitation, aggressive behavior, reduced consciousness, and somnolence. There is no specific antidote for Peranel overdose. Anyone who has taken more than the prescribed dose of Peranel, or shows signs of overdose, should seek immediate medical attention or contact emergency services / a poison control center right away. Management is supportive and symptomatic, including monitoring of vital signs and general supportive care under medical supervision; because Peranel is highly protein-bound, hemodialysis is not expected to be effective in removing it.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: Use Peranel with caution in elderly patients, who may be more sensitive to dizziness, somnolence, gait disturbance and fall risk; no specific dose adjustment is required based on age alone, but individualized titration and monitoring are advised.
• Hepatic impairment: Lower starting dose and slower titration required in mild-to-moderate impairment; not recommended in severe hepatic impairment (see Dosage and Administration).
• Renal impairment: No adjustment generally needed in mild-to-moderate impairment; use with caution in severe renal impairment as it has not been well studied.
• Women of childbearing potential: Counsel regarding the reduced effectiveness of progestin-containing hormonal contraceptives at higher doses of Peranel and the need for additional contraception (see Interactions); discuss pregnancy planning with a physician.
• Pediatric patients: Use only within the approved age range for each indication; safety and efficacy of Peranel have not been established in younger children outside the approved range.

The duration of treatment with Peranel is individualized and determined by the treating physician based on seizure control, tolerability, and the overall antiepileptic treatment plan. Peranel is generally intended for long-term, continuous use as adjunctive therapy in chronic epilepsy management, and should not be stopped or its dose changed without medical advice, given the risk of seizure recurrence with abrupt discontinuation.

Antiepileptic drugs (AEDs); selective AMPA-type glutamate receptor antagonists (class of Perampanel).

Perampanel works by selectively and non-competitively blocking the AMPA subtype of glutamate receptors on postsynaptic neurons, thereby reducing glutamate-mediated excitatory neurotransmission that contributes to the initiation and spread of seizures (see Pharmacology for details).

Peranel is approved as adjunctive therapy for partial-onset seizures and, separately, for primary generalized tonic-clonic seizures in pediatric patients within the specific age ranges established in the approved product labeling. Dosing in children generally follows the same gradual titration principle as in adults, individualized to body weight, seizure type, and tolerability, and should be supervised by a pediatrician or pediatric neurologist. Safety and efficacy of Peranel have not been established in children below the approved minimum age for each indication, and caregivers should be specifically counseled about the risk of neuropsychiatric side effects (irritability, aggressive behavior) in this age group.